Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation

BACKGROUND: To evaluate the efficacy and safety of telbivudine in chronic hepatitis B women during the second and third trimesters of pregnancy. METHODS: The week 12–34 of pregnant women were screened in this prospective non-intervention study, with HBV DNA > 10(6) IU/mL and alanine aminotransfer...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Li-fen, Zheng, Jian-ming, Zheng, Li-qing, Gao, Hai-bing, Chen, Li-xia, Xu, Qing-ling, Chai, Yi-hong, Zhang, Xin, Pan, Chen, Yao, Lv-feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626355/
https://www.ncbi.nlm.nih.gov/pubmed/31299917
http://dx.doi.org/10.1186/s12879-019-4250-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626355/
https://www.ncbi.nlm.nih.gov/pubmed/31299917
http://dx.doi.org/10.1186/s12879-019-4250-6

Ejemplares similares